Risankizumab in Patients with Psoriasis with Current or Previous Malignancy: A Multicenter, Retrospective Real-World Study
Marco Sousa, Ana Luísa João, Martim Luz, Pedro Mendes-Bastos, Ângela Roda, Luiz Leite, Joana Valério, Ana Ferreirinha, Bárbara Leal, Maria João Paiva Lopes, Rita Pimenta, Paulo Ferreira, Tiago Torres
Springer Nature ·
2025-10-01
· DOI 10.1007/s40259-025-00745-x
The publisher did not provide an abstract — full text is available via the link below.
Marco Sousa, Ana Luísa João, Martim Luz, Pedro Mendes-Bastos, Ângela Roda, Luiz Leite et al. Risankizumab in Patients with Psoriasis with Current or Previous Malignancy: A Multicenter, Retrospective Real-World Study. // BioDrugs. – 2025. – DOI: 10.1007/s40259-025-00745-x. – URL: https://doi.org/10.1007/s40259-025-00745-x
Marco Sousa, Ana Luísa João, Martim Luz, Pedro Mendes-Bastos, Ângela Roda, Luiz Leite, Joana Valério, Ana Ferreirinha, Bárbara Leal, Maria João Paiva Lopes, Rita Pimenta, Paulo Ferreira, & Tiago Torres (2025). Risankizumab in Patients with Psoriasis with Current or Previous Malignancy: A Multicenter, Retrospective Real-World Study. BioDrugs. https://doi.org/10.1007/s40259-025-00745-x
Marco Sousa, et al. “Risankizumab in Patients with Psoriasis with Current or Previous Malignancy: A Multicenter, Retrospective Real-World Study.” BioDrugs, 2025. doi:10.1007/s40259-025-00745-x.
@article{Sousa2025,
title = {Risankizumab in Patients with Psoriasis with Current or Previous Malignancy: A Multicenter, Retrospective Real-World Study},
author = {Sousa, Marco and João, Ana Luísa and Luz, Martim and Mendes-Bastos, Pedro and Roda, Ângela and Leite, Luiz and Valério, Joana and Ferreirinha, Ana and Leal, Bárbara and Lopes, Maria João Paiva and Pimenta, Rita and Ferreira, Paulo and Torres, Tiago},
journal = {BioDrugs},
year = {2025},
doi = {10.1007/s40259-025-00745-x},
url = {https://doi.org/10.1007/s40259-025-00745-x}
}